Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia

New England Journal of Medicine

Volumn 346, Issue 10, 2002, Pages 747-750

  Davidson, Ross ^a   Cavalcanti, Rodrigo ^b,d   Brunton, James L ^b,c,d   Bast, Darrin J ^c,d   De Azavedo, Joyce C S ^c,d   Kibsey, Pamela ^e   Fleming, Christine ^f   Low, Donald E ^b,c,d,f  

^a QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e VICTORIA GENERAL HOSPITAL   (Canada)

^f Ontario Medical Association   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGED; ANAMNESIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; FEMALE; HUMAN; LOBAR PNEUMONIA; MALE; PRIORITY JOURNAL; SPUTUM ANALYSIS; STREPTOCOCCUS PNEUMONIAE; THORAX RADIOGRAPHY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, BACTERIAL; FATAL OUTCOME; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OFLOXACIN; PNEUMONIA, PNEUMOCOCCAL; STREPTOCOCCUS PNEUMONIAE; TREATMENT FAILURE;

EID: 0037035122     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa012122     Document Type: Article

References (22)

1. Practice guidelines for the management of community-acquired pneumonia in adults
2. Guidelines for the management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, antimicrobial therapy, and prevention
3. Canadian guidelines for the initial management of community-acquired pneumonia: An evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society
4. Management of community-acquired pneumonia in the era of pneumococcal resistance: A report from the drug-resistant Streptococcus pneumoniae Therapeutic Working Group
5. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia
6. CAP5 Moxifloxacin Study Group. Oral moxifloxacin vs high-dosage amoxicilin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults
7. Comparison of genomic DNAs of different enterococcal isolates using restriction endonucleases with infrequent recognition sites
8. Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: Contributions of type II topoisomerase mutations and efflux to levels of resistance
9. Risk factors for acquisition of levofloxacin- resistant Streptococcus pneumoniae: A case-control study
10. Mechanisms of action of antimicrobials: Focus on fluoro-quinolones
11. Analysis for a limited number of gene codons can predict drug resistance of Mycobacterium tuberculosis in a high-incidence community
12. The specific polysaccharide content ofpneumonic lungs
13. Bacterial infection in chronic obstructive pulmonary disease: A study of stable and exacerbated outpatients using the protected specimen brush
14. A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae
15. Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmaco-kinetic model
16. Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials
17. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses
18. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada
19. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong
20. Analysis of ciprofloxacin activity against Streptococcus pneumoniae after 10 years of use in the United States
21. Evaluation of susceptibility testing to detect fluoroquinolone resistance mechanisms in Streptococcus pneumoniae